CLINICAL_TRIALS trial_result · 2025-06-11

Clinical Trial Update: Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer [Phase 4]

Pfizer's Phase 4 study of lorlatinib in ALK-positive non-small cell lung cancer has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 4 | Status: COMPLETED | Results posted: 2025-06-11